One Firm's Pain Is This Firm's Gain; Noven Pharmaceuticals; Miami, Fla. noven.com.(HEALTH & MEDICINE)(UNDER THE MICROSCOPE)

Publication: Investor's Business Daily

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 Investor's Business Daily, Inc.

Byline: Kirk Shinkle

A billion-dollar pain patch is set to hit the generic market, and Noven Pharmaceuticals is one of a handful of medical patch makers that could cash in.

Johnson & Johnson's Duragesic, the world's top-selling patch, is set to go off patent Jan. 23. Analysts estimate it has $1.3 billion in annual sales.

When Duragesic does lose patent exclusivity -- and J&J is trying to extend its patent -- Noven could have...

Read the full article for free courtesy of your local library.